Je was op zoek naar: perkutanja (Maltees - Engels)

rotot oħrajn (teħid tan-nifs, perkutanja kif xieraq)
other routes (inhalation, percutaneous as appropriate)

it-tossiċità akuta perkutanja tas-sustanza attiva trid dejjem tiġi rrappurtata.
the acute percutaneous toxicity of the active substance must always be reported.

studji dwar assorbiment, distribuzzjoni u eskrezjoni - wara amministrazzjoni kemm mill-ħalq kif ukoll perkutanja.
absorption, distribution and excretion studies - following both oral and percutaneous administration

in-numru ta’ pazjenti li għaddew mill-punt primarju ta’ tmiem [mewt kardjovaskulari (cv), infart mijokardijaku (mi) jew puplesija] kien 582 (9.3%) fil-grupp ikkurat bi clopidogrel u 719 (11.4%) fil- grupp ikkurat bil-plaċebo, li jissarraf fi tnaqqis fir-riskju relattiv ta’ 20% (95% ci ta’ 10%-28%; p=0.00009) għall-grupp ikkurat bi clopidogrel (tnaqqis fir-riskju relattiv ta’ 17% f’pazjenti li kienu kkurati b’mod konservattiv, 29% meta kellhom anġoplastija koronarja transluminali perkutanja (ptca) bi stent jew mingħajru u 10% meta kellhom trapjant ta' bajpass f'arterja koronarja (cabg)).
the number of patients experiencing the primary endpoint [cardiovascular (cv) death, myocardial infarction (mi), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% ci of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (ptca) with or without stent and 10% when they underwent coronary artery bypass graft (cabg)).